Latanoprost-PPDS
DrugSustained delivery for 12 weeks
NCT Number: NCT01481051
The purpose of this study is to evaluate the efficacy, safety and duration of the L-PPDS (latanoprost punctal plug delivery system) at different dose levels.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Sall Research Medical Center, Inc, Artesia, California, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Sustained delivery for 12 weeks
Time frame: 12 weeks to baseline
Mati Therapeutics Inc.
Industry
PPL GLAU 12: A Phase 2 Dose Evaluation Study for the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06689696
Eye Diseases, GLAUCOMA 1, OPEN ANGLE, D (Disorder)
Fullerton, California, United States
View Trial DetailsNCT01481077
Eye Diseases, Glaucoma
Springdale, Arkansas, United States
View Trial DetailsNCT07550712
Eye Diseases, Glaucoma
Taipei, Taiwan
View Trial DetailsNCT07318428
Age Related Macular Degeneration, Cardiovascular Diseases
Busan, South Korea
View Trial Details